Analysts Issue Forecasts for APRE Q1 Earnings

Aprea Therapeutics, Inc. (NASDAQ:APRE) – Equities researchers at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for shares of Aprea Therapeutics in a research note issued on Monday, March 16th. HC Wainwright analyst J. Pantginis forecasts that the company will post earnings per share of ($0.23) for the quarter. HC Wainwright has a “Buy” rating and a $4.00 price target on the stock. The consensus estimate for Aprea Therapeutics’ current full-year earnings is ($2.55) per share. HC Wainwright also issued estimates for Aprea Therapeutics’ Q2 2026 earnings at ($0.24) EPS, Q3 2026 earnings at ($0.22) EPS, Q4 2026 earnings at ($0.21) EPS, FY2026 earnings at ($0.90) EPS, FY2027 earnings at ($0.90) EPS and FY2028 earnings at ($0.94) EPS.

Other equities analysts have also issued research reports about the stock. Zacks Research upgraded shares of Aprea Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, February 16th. Wedbush decreased their price target on shares of Aprea Therapeutics from $11.00 to $7.00 and set an “outperform” rating on the stock in a research note on Tuesday, February 10th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Aprea Therapeutics in a report on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $5.50.

Aprea Therapeutics Price Performance

Aprea Therapeutics stock opened at $0.73 on Wednesday. Aprea Therapeutics has a 1 year low of $0.55 and a 1 year high of $2.65. The firm’s 50 day moving average price is $0.79 and its 200-day moving average price is $1.10. The stock has a market cap of $5.11 million, a P/E ratio of -0.37 and a beta of 1.42.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings results on Monday, March 16th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.06. Aprea Therapeutics had a negative return on equity of 96.33% and a negative net margin of 4,405.59%.The business had revenue of $0.00 million during the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aprea Therapeutics stock. Jane Street Group LLC purchased a new position in Aprea Therapeutics, Inc. (NASDAQ:APRE) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 46,621 shares of the company’s stock, valued at approximately $40,000. Jane Street Group LLC owned about 0.67% of Aprea Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC). 34.19% of the stock is currently owned by hedge funds and other institutional investors.

Aprea Therapeutics News Summary

Here are the key news stories impacting Aprea Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $4 price target while raising its FY2026–FY2028 EPS forecasts (reducing expected losses), signaling improved analyst sentiment that could support upside over time. HC Wainwright Forecasts and Rating
• Neutral Sentiment: Multiple HC Wainwright quarterly EPS projections were published (Q1–Q4 2026 and FY2026–FY2028), giving investors updated modeling inputs but not yet translating to revenue or near‑term cash‑flow visibility. HC Wainwright Detail
• Neutral Sentiment: Short‑interest reports for mid‑March show effectively zero reported short interest (days‑to‑cover 0.0), which suggests no meaningful short squeeze dynamic but also indicates the reported short data may be unreliable or not informative for current flows.
• Neutral Sentiment: An earnings announcement is expected soon, which could create short‑term volatility as investors reassess guidance and cash‑position disclosures. Earnings Date Preview
• Negative Sentiment: Despite analyst upgrades, Aprea remains a pre‑revenue, heavily loss‑making biotech (consensus and company estimates show continued negative EPS; current consensus FY EPS is deeply negative), and its very small market cap and thin liquidity amplify downside risk if sentiment shifts.

Aprea Therapeutics Company Profile

Aprea Therapeutics is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies that restore tumor suppressor function in cancers driven by TP53 mutations. The company’s lead investigational agent, eprenetapopt (APR-246), is designed to convert mutant p53 protein into a form that induces programmed cell death in malignant cells. Aprea’s research focuses on hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), as well as solid tumors harboring TP53 mutations.

Eprenetapopt has advanced through multiple clinical trials, including pivotal studies assessing its efficacy in combination with hypomethylating agents for patients with MDS.